These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27424166)

  • 1. Synthetic cannabinoids to avoid urine drug screens: Implications for contingency management and other treatments for drug dependence.
    Ninnemann AL; Lechner WV; Borges A; Lejuez CW
    Addict Behav; 2016 Dec; 63():72-3. PubMed ID: 27424166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motivation and Contingency Management Treatments for Substance Use Disorders.
    Walter KN; Petry NM
    Curr Top Behav Neurosci; 2016; 27():569-81. PubMed ID: 25762429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal.
    Cooper ZD
    Curr Psychiatry Rep; 2016 May; 18(5):52. PubMed ID: 27074934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of a novel immunoassay for the detection of synthetic cannabinoids and metabolites in urine specimens.
    Arntson A; Ofsa B; Lancaster D; Simon JR; McMullin M; Logan B
    J Anal Toxicol; 2013 Jun; 37(5):284-90. PubMed ID: 23625703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contingency management: utility in the treatment of drug abuse disorders.
    Stitzer ML; Vandrey R
    Clin Pharmacol Ther; 2008 Apr; 83(4):644-7. PubMed ID: 18305456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contingency management for substance use disorders in Spain: Implications for research and practice.
    Secades-Villa R; García-Rodríguez O; Fernández-Hermida JR
    Prev Med; 2015 Nov; 80():82-8. PubMed ID: 26164071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel psychoactive substance use by US adolescents: Characteristics associated with use of synthetic cannabinoids and synthetic cathinones.
    Patrick ME; O'Malley PM; Kloska DD; Schulenberg JE; Johnston LD; Miech RA; Bachman JG
    Drug Alcohol Rev; 2016 Sep; 35(5):586-90. PubMed ID: 26711540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis.
    Kassai S; Pintér JN; Rácz J; Böröndi B; Tóth-Karikó T; Kerekes K; Gyarmathy VA
    Harm Reduct J; 2017 Feb; 14(1):9. PubMed ID: 28187774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in 'herbal mixtures' using LC-MS/MS techniques.
    Hutter M; Broecker S; Kneisel S; Auwärter V
    J Mass Spectrom; 2012 Jan; 47(1):54-65. PubMed ID: 22282090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic Cannabinoids-Further Evidence Supporting the Relationship Between Cannabinoids and Psychosis.
    Fattore L
    Biol Psychiatry; 2016 Apr; 79(7):539-48. PubMed ID: 26970364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population.
    Poling J; Oliveto A; Petry N; Sofuoglu M; Gonsai K; Gonzalez G; Martell B; Kosten TR
    Arch Gen Psychiatry; 2006 Feb; 63(2):219-28. PubMed ID: 16461866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample.
    Winstock A; Lynskey M; Borschmann R; Waldron J
    J Psychopharmacol; 2015 Jun; 29(6):698-703. PubMed ID: 25759401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contingency Management Abstinence Incentives: Cost and Implications for Treatment Tailoring.
    Cunningham C; Stitzer M; Campbell AN; Pavlicova M; Hu MC; Nunes EV
    J Subst Abuse Treat; 2017 Jan; 72():134-139. PubMed ID: 26482136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Fast and Comprehensive Analysis of 32 Synthetic Cannabinoids Using Agilent Triple Quadrupole LC-MS-MS.
    Borg D; Tverdovsky A; Stripp R
    J Anal Toxicol; 2017 Jan; 41(1):6-16. PubMed ID: 27681343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. International trends in spice use: Prevalence, motivation for use, relationship to other substances, and perception of use and safety for synthetic cannabinoids.
    Loeffler G; Delaney E; Hann M
    Brain Res Bull; 2016 Sep; 126(Pt 1):8-28. PubMed ID: 27108542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contingency management for treatment of substance use disorders: a meta-analysis.
    Prendergast M; Podus D; Finney J; Greenwell L; Roll J
    Addiction; 2006 Nov; 101(11):1546-60. PubMed ID: 17034434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A meta-analytic review of psychosocial interventions for substance use disorders.
    Dutra L; Stathopoulou G; Basden SL; Leyro TM; Powers MB; Otto MW
    Am J Psychiatry; 2008 Feb; 165(2):179-87. PubMed ID: 18198270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contingency management for treatment of substance abuse.
    Stitzer M; Petry N
    Annu Rev Clin Psychol; 2006; 2():411-34. PubMed ID: 17716077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of drugs of abuse in urine of drivers involved in road accidents in France: a collaborative study.
    Marquet P; Delpla PA; Kerguelen S; Bremond J; Facy F; Garnier M; Guery B; Lhermitte M; Mathé D; Pelissier AL; Renaudeau C; Vest P; Seguela JP
    J Forensic Sci; 1998 Jul; 43(4):806-11. PubMed ID: 9670503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The construct and predictive validity of different approaches to combining urine and self-reported drug use measures among older adolescents after substance abuse treatment.
    Lennox R; Dennis ML; Ives M; White MK
    Am J Addict; 2006; 15 Suppl 1():92-101. PubMed ID: 17182424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.